Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax RateWages, Salaries and Other
Others
Ratios

Bicycle Therapeutics (BCYC) Restructuring Costs (2024 - 2026)

Bicycle Therapeutics (BCYC) has disclosed Restructuring Costs for 3 consecutive years, with $2.5 million as the latest value for Q1 2026.

  • For Q1 2026, Restructuring Costs rose 15.69% year-over-year to $2.5 million; the TTM value through Mar 2026 reached $9.9 million, up 7.56%, while the annual FY2025 figure was $9.6 million, 5.86% up from the prior year.
  • Restructuring Costs hit $2.5 million in Q1 2026 for Bicycle Therapeutics, down from $2.6 million in the prior quarter.
  • Across five years, Restructuring Costs topped out at $2.6 million in Q4 2024 and bottomed at $1.9 million in Q2 2024.
  • Average Restructuring Costs over 3 years is $2.4 million, with a median of $2.5 million recorded in 2025.
  • On a YoY basis, Restructuring Costs climbed as much as 21.45% in 2025 and fell as far as 2.29% in 2025.
  • Bicycle Therapeutics' Restructuring Costs stood at $2.6 million in 2024, then changed by 0.0% to $2.6 million in 2025, then dropped by 1.82% to $2.5 million in 2026.
  • According to Business Quant data, Restructuring Costs over the past three periods came in at $2.5 million, $2.6 million, and $2.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.